Skip to main content
Triangle logo TriangleGet started

Belzutifan (NCT07700758)

A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01): a one-minute explainerNCT077007581 min

Belzutifan trial for Malignant Neoplasm (NCT07700758). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adolescents aged 12–17 with advanced or unresectable pheochromocytoma/paraganglioma or wild-type gastrointestinal stromal tumors, or localized tumors linked to von Hippel–Lindau disease. Measurable disease is required.

The idea: belzutifan blocks HIF-2α, a protein involved in tumor growth and survival. Tablets are taken once daily for about two years, with dosing based on weight. Prior HIF-2α inhibitor treatment is excluded.

This phase 2 study plans 15 patients. Merck sponsors the study; the University of Iowa in Iowa City is the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.